Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

Inclusion Criteria

• •Participants with a diagnosis of Alzheimer's disease with biomarker confirmation meeting the 2024 Revised criteria for diagnosis and staging of AD: Alzheimer's Association Workgroup.
• •The diagnosis of agitation must meet the International Psychogeriatric Association (IPA) definition of agitation.
• •History of agitation with onset at least four weeks prior to Screening
• •MMSE-1 score \< 21
• •NPI-NH agitation/aggression sub-score ≥ 4.
• •Capable of self-locomotion (alone or with the aid of an assistive device); wheelchairs and other mobility aids are acceptable.